Selective activation of anti-CD73 mechanisms in control of primary tumors and metastases.

Vijayan, Dipti; Barkauskas, Deborah S; Stannard, Kimberley; Sult, Erin; Buonpane, Rebecca; Takeda, Kazuyoshi; Teng, Michele W L; Sachsenmeier, Kris; Hay, Carl; Smyth, Mark J

Vijayan, Dipti; Barkauskas, Deborah S; Stannard, Kimberley; Sult, Erin; Buonpane, Rebecca; Takeda, Kazuyoshi; Teng, Michele W L; Sachsenmeier, Kris; Hay, Carl; Smyth, Mark J.

Afiliação

Vijayan D; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Barkauskas DS; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Stannard K; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Sult E; MedImmune, LLC., Gaithersburg, MD, USA.
Buonpane R; MedImmune, LLC., Gaithersburg, MD, USA.
Takeda K; Division of Cell Biology, Biomedical Research Center, Graduate School of Medicine, Juntendo University, Bunkyo-ku, Tokyo, Japan.
Teng MWL; Cancer Immunoregulation and Immunotherapy Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.
Sachsenmeier K; AstraZeneca, PLC, Waltham, MA, USA.
Hay C; MedImmune, LLC., Gaithersburg, MD, USA.
Smyth MJ; Immunology in Cancer and Infection Laboratory, QIMR Berghofer Medical Research Institute, Herston, Queensland, Australia.

Oncoimmunology ; 6(5): e1312044, 2017.

Article em En | MEDLINE | ID: mdl-28638737

Palavras-chave

Adenosine; CD73; combination therapy; immunotherapy; tumor

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Prognostic_studies Idioma: En Revista: Oncoimmunology Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Austrália

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google